Advanced search
Publication Cover
OncoTargets and Therapy Volume 11, 2018 - Issue
Submit an article Journal homepage
60
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations

Limin LiDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Xiaoqian ZhangDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Hongjuan YuDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Mingwen ZhangDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Mengyuan XuDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Jie LiuDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Yueyue FuDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Hongbin MengDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Chengfang LyuDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]
,
Xiaoxia LiDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]Correspondence[email protected] [email protected]
&
Jin ZhouDepartment of Hematology, Institute of Hematology and Oncology of Heilongjiang Province, Hematology and Oncology Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China, [email protected]; [email protected]Correspondence[email protected] [email protected]
 show all
Pages 6863-6870 | Published online: 12 Oct 2018

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Zhibo Guo, Dan Guo, Desheng Kong, Sicheng Bian, Leilei Lin, Shengjin Fan, Qi Li, Yanqiu Zhao, Yanmeng Jiang, Jiangrong Yan, Zheren Wang, Lili Sun & Yinghua Li. (2023) Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study. Hematology 28:1.
Read now

Articles from other publishers (5)

Elly Y Arwanih, Melva Louisa, Ikhwan Rinaldi & Septelia I Wanandi. (2022) Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review. Cureus.
Crossref
Lei Gao, Yanqi Zhang, Sanbin Wang, Peiyan Kong, Yi Su, Jiong Hu, Ming Jiang, Hai Bai, Tao Lang, Jishi Wang, Li Liu, Tonghua Yang, Xiaobing Huang, Fang Liu, Shifeng Lou, Yao Liu, Cheng Zhang, Hong Liu, Li Gao, Jia Liu, Lidan Zhu, Qin Wen, Ting Chen, Ping Wang, Jun Rao, Min Mao, Cunbang Wang, Xianlin Duan, Le Luo, Xiangui Peng, Kaniel Cassady, Jiang F. Zhong & Xi Zhang. (2020) Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. Journal of Clinical Oncology 38:36, pages 4249-4259.
Crossref
Kristin Koenig & Alice Mims. (2020) Relapsed or primary refractory AML. Current Opinion in Hematology 27:2, pages 108-114.
Crossref
Francisco Caiado, Diogo Maia-Silva, Carolina Jardim, Nina Schmolka, Tânia Carvalho, Cláudia Reforço, Rita Faria, Branka Kolundzija, André E. Simões, Tuncay Baubec, Christopher R. Vakoc, Maria Gomes da Silva, Markus G. Manz, Ton N. Schumacher, Håkan Norell & Bruno Silva-Santos. (2019) Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nature Communications 10:1.
Crossref
Mingqing Wu, Lu Sheng, Maosheng Cheng, Haojie Zhang, Yizhou Jiang, Shuibin Lin, Yu Liang, Fengyu Zhu, Zhenqing Liu, Yingyin Zhang, Xiuhong Zhang, Qian Gao, Demeng Chen, Jiong Li & Yang Li. (2019) Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene 38:27, pages 5425-5439.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.